Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia

HOME

HELP

FEEDBACK

SUBSCRIPTIONS

Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia

AR Perez-Atayde, SE Sallan, U Tedrow, S Connors, E Allred and J Folkman
Department of Pathology, Children's Hospital, Boston, Massachusetts 02115, USA.

It has been shown that solid tumors progress in concert with an induction of tumor angiogenesis. It is not known, however, whether a similar phenomenon occurs in leukemia. Angiogenesis was characterized immunohistochemically by factor VIII staining of bone marrow biopsies and quantified by assessment of microvessel density using previously described techniques. We evaluated bone marrow biopsies from 40 children with newly diagnosed, untreated acute lymphoblastic leukemia. In 22 of the patients, we also evaluated angiogenesis after the completion of remission induction chemotherapy. Control specimens were obtained from children undergoing staging evaluations at the time of diagnosis of solid tumors and lymphomas. Microvessels were counted throughout the entire core specimen in consecutive x 200 fields, and a median count per field (cpf) was calculated. In addition, the number of microvessels in the single x 200 field with the highest microvessel density was designated as the "hot spot." Biopsies from children with leukemia and from controls showed median microvessel densities of 42 and 6 counts per field, respectively (P < or = 0.0001). Microvessel density of the hot spots of leukemia specimens and controls were also significantly different, 51 and 8, respectively (P < or = 0.0001). A computer-aided three-dimensional reconstruction model of bone marrow vascularity showed a complex, arborizing branching of microvessels in leukemic specimens compared with single, straight microvessels without branching in controls. Urinary basic fibroblast growth factor, a potent angiogenic factor, was measured in 22 of the children with newly diagnosed leukemia and in 39 normal, age-matched controls. Urinary basic fibroblast growth factor levels were increased in all 22 patients before treatment, were variable during induction chemotherapy, and demonstrated statistically insignificant decreases at the time of complete remission. These findings suggest that leukemia cells induce angiogenesis in the bone marrow and that leukemia might be angiogenesis dependent and raise the possibility for a role of antiangiogenic drugs in the treatment of leukemia.

This article has been cited by other articles:

M. T. Scupoli, M. Donadelli, F. Cioffi, M. Rossi, O. Perbellini, G. Malpeli, S. Corbioli, F. Vinante, M. Krampera, M. Palmieri, et al.
Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-{kappa}B and JNK/AP-1 pathways
Haematologica, April 1, 2008; 93(4): 524 - 532.
[Abstract] [Full Text] [PDF]

D. Cervi, T.-T. Yip, N. Bhattacharya, V. N. Podust, J. Peterson, A. Abou-Slaybi, G. N. Naumov, E. Bender, N. Almog, J. E. Italiano Jr, et al.
Platelet-associated PF-4 as a biomarker of early tumor growth
Blood, February 1, 2008; 111(3): 1201 - 1207.
[Abstract] [Full Text] [PDF]

E. Zetterberg, A. M. Vannucchi, A. R. Migliaccio, W. Vainchenker, M. Tulliez, R. Dickie, H. Hasselbalch, R. Rogers, and J. Palmblad
Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows
Haematologica, May 1, 2007; 92(5): 597 - 604.
[Abstract] [Full Text] [PDF]

D. Cervi, Y. Shaked, M. Haeri, T. Usenko, C. R. Lee, J. J. Haigh, A. Nagy, R. S. Kerbel, E. Yefenof, and Y. Ben-David
Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia
Blood, March 1, 2007; 109(5): 2139 - 2146.
[Abstract] [Full Text] [PDF]

S. Shalapour, A. Zelmer, M. Pfau, E. Moderegger, C. Costa-Blechschmidt, F. K.H. van Landeghem, T. Taube, I. Fichtner, C. Buhrer, G. Henze, et al.
The Thalidomide Analogue, CC-4047, Induces Apoptosis Signaling and Growth Arrest in Childhood Acute Lymphoblastic Leukemia Cells In vitro and In vivo.
Clin. Cancer Res., September 15, 2006; 12(18): 5526 - 5532.
[Abstract] [Full Text] [PDF]

S. Indraccolo, L. Stievano, S. Minuzzo, V. Tosello, G. Esposito, E. Piovan, R. Zamarchi, L. Chieco-Bianchi, and A. Amadori
Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment.
PNAS, March 14, 2006; 103(11): 4216 - 4221.
[Abstract] [Full Text] [PDF]

W. Liu, M. Guo, Y.-B. Xu, D. Li, Z.-N. Zhou, Y.-L. Wu, Z. Chen, S. C. Kogan, and G.-Q. Chen
Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia
Blood, January 15, 2006; 107(2): 698 - 707.
[Abstract] [Full Text] [PDF]

W. Fureder, M.-T. Krauth, W. R. Sperr, K. Sonneck, I. Simonitsch-Klupp, L. Mullauer, M. Willmann, H.-P. Horny, and P. Valent
Evaluation of Angiogenesis and Vascular Endothelial Growth Factor Expression in the Bone Marrow of Patients with Aplastic Anemia
Am. J. Pathol., January 1, 2006; 168(1): 123 - 130.
[Abstract] [Full Text] [PDF]

L. F. Costa, M. Balcells, E. R. Edelman, L. M. Nadler, and A. A. Cardoso
Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-{kappa}B
Blood, January 1, 2006; 107(1): 285 - 292.
[Abstract] [Full Text] [PDF]

S. Faderl, K.-A. Do, M. M. Johnson, M. Keating, S. O'Brien, I. Jilani, A. Ferrajoli, F. Ravandi-Kashani, C. Aguilar, A. Dey, et al.
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia
Blood, December 15, 2005; 106(13): 4303 - 4307.
[Abstract] [Full Text] [PDF]

M. Chavez-MacGregor, A. Aviles-Salas, D. Green, A. Fuentes-Alburo, C. Gomez-Ruiz, and A. Aguayo
Angiogenesis in the Bone Marrow of Patients with Breast Cancer
Clin. Cancer Res., August 1, 2005; 11(15): 5396 - 5400.
[Abstract] [Full Text] [PDF]

Y. Shaked, D. Cervi, M. Neuman, L. Chen, G. Klement, C. R. Michaud, M. Haeri, B. J. Pak, R. S. Kerbel, and Y. Ben-David
The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells
Blood, June 1, 2005; 105(11): 4500 - 4507.
[Abstract] [Full Text] [PDF]

K. Podar and K. C. Anderson
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Blood, February 15, 2005; 105(4): 1383 - 1395.
[Abstract] [Full Text] [PDF]

J. LeCouter, C. Zlot, M. Tejada, F. Peale, and N. Ferrara
Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization
PNAS, November 30, 2004; 101(48): 16813 - 16818.
[Abstract] [Full Text] [PDF]

M G Alexandrakis, F H Passam, C Dambaki, C A Pappa, and E N Stathopoulos
The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma
J. Clin. Pathol., August 1, 2004; 57(8): 856 - 860.
[Abstract] [Full Text] [PDF]

S. Kumar, T. E. Witzig, and S. V. Rajkumar
Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies
J. Clin. Oncol., June 15, 2004; 22(12): 2477 - 2488.
[Abstract] [Full Text] [PDF]

H. X. Chen
Expanding the Clinical Development of Bevacizumab
Oncologist, June 1, 2004; 9(suppl_1): 27 - 35.
[Abstract] [Full Text] [PDF]

A. Ruddell, P. Mezquita, K. A. Brandvold, A. Farr, and B. M. Iritani
B Lymphocyte-Specific c-Myc Expression Stimulates Early and Functional Expansion of the Vasculature and Lymphatics during Lymphomagenesis
Am. J. Pathol., December 1, 2003; 163(6): 2233 - 2245.
[Abstract] [Full Text]

F. J. Giles, A. T. Stopeck, L. R. Silverman, J. E. Lancet, M. A. Cooper, A. L. Hannah, J. M. Cherrington, A.-M. O'Farrell, H. A. Yuen, S. G. Louie, et al.
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
Blood, August 1, 2003; 102(3): 795 - 801.
[Abstract] [Full Text] [PDF]

X. Chen, Z. Ai, M. Rasmussen, P. Bajcsy, L. Auvil, M. Welge, L. Leach, S. Vangveeravong, A. J. Maniotis, and R. Folberg
Three-Dimensional Reconstruction of Extravascular Matrix Patterns and Blood Vessels in Human Uveal Melanoma Tissue: Techniques and Preliminary Findings
Invest. Ophthalmol. Vis. Sci., July 1, 2003; 44(7): 2834 - 2840.
[Abstract] [Full Text] [PDF]

G. Schuch, M. Machluf, G. Bartsch Jr, M. Nomi, H. Richard, A. Atala, and S. Soker
In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo
Blood, December 15, 2002; 100(13): 4622 - 4628.
[Abstract] [Full Text] [PDF]

P. O. Iversen, C. A. Drevon, and J. E. Reseland
Prevention of leptin binding to its receptor suppresses rat leukemic cell growth by inhibiting angiogenesis
Blood, December 1, 2002; 100(12): 4123 - 4128.
[Abstract] [Full Text] [PDF]

F. A. Scappaticci
Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies
J. Clin. Oncol., September 15, 2002; 20(18): 3906 - 3927.
[Abstract] [Full Text] [PDF]

E. S. J. M. de Bont, V. Fidler, T. Meeuwsen, F. Scherpen, K. Hahlen, and W. A. Kamps
Vascular Endothelial Growth Factor Secretion Is an Independent Prognostic Factor for Relapse-free Survival in Pediatric Acute Myeloid Leukemia Patients
Clin. Cancer Res., September 1, 2002; 8(9): 2856 - 2861.
[Abstract] [Full Text] [PDF]

L. Hlatky, P. Hahnfeldt, and J. Folkman
Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us
J Natl Cancer Inst, June 19, 2002; 94(12): 883 - 893.
[Full Text] [PDF]

R. A. Mesa, C. A. Hanson, C.-Y. Li, S.-Y. Yoon, S. V. Rajkumar, G. Schroeder, and A. Tefferi
Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia
Blood, May 13, 2002; 99(11): 4131 - 4137.
[Abstract] [Full Text] [PDF]

F. Wimazal, J.-H. Jordan, W. R. Sperr, A. Chott, S. Dabbass, K. Lechner, H. P. Horny, and P. Valent
Increased Angiogenesis in the Bone Marrow of Patients with Systemic Mastocytosis
Am. J. Pathol., May 1, 2002; 160(5): 1639 - 1645.
[Abstract] [Full Text] [PDF]

M. E. El-Sabban, R. A. Merhi, H. A. Haidar, B. Arnulf, H. Khoury, J. Basbous, J. Nijmeh, H. de The, O. Hermine, and A. Bazarbachi
Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells
Blood, May 1, 2002; 99(9): 3383 - 3389.
[Abstract] [Full Text] [PDF]

S. Dias, M. Choy, K. Alitalo, and S. Rafii
Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy
Blood, March 15, 2002; 99(6): 2179 - 2184.
[Abstract] [Full Text] [PDF]

R. Koomagi, F. Zintl, A. Sauerbrey, and M. Volm
Vascular Endothelial Growth Factor in Newly Diagnosed and Recurrent Childhood Acute Lymphoblastic Leukemia as Measured by Real-Time Quantitative Polymerase Chain Reaction
Clin. Cancer Res., November 1, 2001; 7(11): 3381 - 3384.
[Abstract] [Full Text] [PDF]

E. S. J. M. de Bont, J. E. J. Guikema, F. Scherpen, T. Meeuwsen, W. A. Kamps, E. Vellenga, and N. A. Bos
Mobilized Human CD34+ Hematopoietic Stem Cells Enhance Tumor Growth in a Nonobese Diabetic/Severe Combined Immunodeficient Mouse Model of Human Non-Hodgkin's Lymphoma
Cancer Res., October 1, 2001; 61(20): 7654 - 7659.
[Abstract] [Full Text] [PDF]

J. L. Gabrilove
Angiogenic Growth Factors: Autocrine and Paracrine Regulation of Survival in Hematologic Malignancies
Oncologist, October 1, 2001; 6(2008): 4 - 7.
[Abstract] [Full Text] [PDF]

A. F. List
Vascular Endothelial Growth Factor Signaling Pathway as an Emerging Target in Hematologic Malignancies
Oncologist, October 1, 2001; 6(2008): 24 - 31.
[Abstract] [Full Text] [PDF]

F. J. Giles
The Vascular Endothelial Growth Factor (VEGF) Signaling Pathway: A Therapeutic Target in Patients with Hematologic Malignancies
Oncologist, October 1, 2001; 6(2008): 32 - 39.
[Abstract] [Full Text] [PDF]

S. Dias, K. Hattori, B. Heissig, Z. Zhu, Y. Wu, L. Witte, D. J. Hicklin, M. Tateno, P. Bohlen, M. A. S. Moore, et al.
Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias
PNAS, September 11, 2001; 98(19): 10857 - 10862.
[Abstract] [Full Text] [PDF]

K. Neben, T. Moehler, G. Egerer, A. Kraemer, J. Hillengass, A. Benner, A. D. Ho, and H. Goldschmidt
High Plasma Basic Fibroblast Growth Factor Concentration Is Associated with Response to Thalidomide in Progressive Multiple Myeloma
Clin. Cancer Res., September 1, 2001; 7(9): 2675 - 2681.
[Abstract] [Full Text] [PDF]

L. Sun, M. Vitolo, and A. Passaniti
Runt-related Gene 2 in Endothelial Cells: Inducible Expression and Specific Regulation of Cell Migration and Invasion
Cancer Res., July 1, 2001; 61(13): 4994 - 5001.
[Abstract] [Full Text] [PDF]

A. R. Kini, L. C. Peterson, M. S. Tallman, and M. W. Lingen
Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid
Blood, June 15, 2001; 97(12): 3919 - 3924.
[Abstract] [Full Text] [PDF]

M. Majka, A. Janowska-Wieczorek, J. Ratajczak, K. Ehrenman, Z. Pietrzkowski, M. A. Kowalska, A. M. Gewirtz, S. G. Emerson, and M. Z. Ratajczak
Numerous growth factors, cytokines, and chemokines are secreted by human CD34+ cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner
Blood, May 15, 2001; 97(10): 3075 - 3085.
[Abstract] [Full Text] [PDF]

S. Wellmann, T. Taube, K. Paal, H. Graf v. Einsiedel, W. Geilen, G. Seifert, C. Eckert, G. Henze, and K. Seeger
Specific Reverse Transcription-PCR Quantification of Vascular Endothelial Growth Factor (VEGF) Splice Variants by LightCycler Technology
Clin. Chem., April 1, 2001; 47(4): 654 - 660.
[Abstract] [Full Text] [PDF]

A. Ferrajoli, T. Manshouri, Z. Estrov, M. J. Keating, S. O’Brien, S. Lerner, M. Beran, H. M. Kantarjian, E. J. Freireich, and M. Albitar
High Levels of Vascular Endothelial Growth Factor Receptor-2 Correlate with Shortened Survival in Chronic Lymphocytic Leukemia
Clin. Cancer Res., April 1, 2001; 7(4): 795 - 799.
[Abstract] [Full Text]

M.-D. Tabone, J. Landman-Parker, B. Arcil, M.-C. Coudert, I. Gerota, M. Benbunan, G. Leverger, and C. Dosquet
Are Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor Prognostic Indicators in Pediatric Patientswith Malignant Solid Tumors?
Clin. Cancer Res., March 1, 2001; 7(3): 538 - 543.
[Abstract] [Full Text]

B. D. Smolich, H. A. Yuen, K. A. West, F. J. Giles, M. Albitar, and J. M. Cherrington
The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
Blood, March 1, 2001; 97(5): 1413 - 1421.
[Abstract] [Full Text] [PDF]

A. Janowska-Wieczorek, M. Majka, J. Ratajczak, and M. Z. Ratajczak
Autocrine/Paracrine Mechanisms in Human Hematopoiesis
Stem Cells, February 1, 2001; 19(2): 99 - 107.
[Abstract] [Full Text]

P. R. Murphy, M. Limoges, F. Dodd, R. T. M. Boudreau, and C. K. L. Too
Fibroblast Growth Factor-2 Stimulates Endothelial Nitric Oxide Synthase Expression and Inhibits Apoptosis by a Nitric Oxide-Dependent Pathway in Nb2 Lymphoma Cells
Endocrinology, January 1, 2001; 142(1): 81 - 88.
[Abstract] [Full Text] [PDF]

R. J. Klasa, A. F. List, and B. D. Cheson
Rational Approaches to Design of Therapeutics Targeting Molecular Markers
Hematology, January 1, 2001; 2001(1): 443 - 462.
[Abstract] [Full Text] [PDF]

P. Salven, A. Orpana, L. Teerenhovi, and H. Joensuu
Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients
Blood, December 1, 2000; 96(12): 3712 - 3718.
[Abstract] [Full Text] [PDF]

R. A. Mesa, C. A. Hanson, S. V. Rajkumar, G. Schroeder, and A. Tefferi
Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia
Blood, November 15, 2000; 96(10): 3374 - 3380.
[Abstract] [Full Text] [PDF]

K. J. Andrews, A. Ribas, L. H. Butterfield, C. M. Vollmer, F. C. Eilber, V. B. Dissette, S. D. Nelson, P. Shintaku, S. Mekhoubad, T. Nakayama, et al.
Adenovirus-Interleukin-12-mediated Tumor Regression in a Murine Hepatocellular Carcinoma Model Is Not Dependent on CD1-restricted Natural Killer T Cells
Cancer Res., November 1, 2000; 60(22): 6457 - 6464.
[Abstract] [Full Text]

H. Chen, A. T. Treweeke, D. C. West, K. J. Till, J. C. Cawley, M. Zuzel, and C. H. Toh
In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells
Blood, November 1, 2000; 96(9): 3181 - 3187.
[Abstract] [Full Text] [PDF]

A. Aguayo, H. Kantarjian, T. Manshouri, C. Gidel, E. Estey, D. Thomas, C. Koller, Z. Estrov, S. O'Brien, M. Keating, et al.
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
Blood, September 15, 2000; 96(6): 2240 - 2245.
[Abstract] [Full Text] [PDF]

G. J. Roboz, S. Dias, G. Lam, W. J. Lane, S. L. Soignet, R. P. Warrell Jr, and S. Rafii
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis
Blood, August 15, 2000; 96(4): 1525 - 1530.
[Abstract] [Full Text] [PDF]

S. V. Rajkumar, T. Leong, P. C. Roche, R. Fonseca, A. Dispenzieri, M. Q. Lacy, J. A. Lust, T. E. Witzig, R. A. Kyle, M. A. Gertz, et al.
Prognostic Value of Bone Marrow Angiogenesis in Multiple Myeloma
Clin. Cancer Res., August 1, 2000; 6(8): 3111 - 3116.
[Abstract] [Full Text]

A. Aguayo, S. O'Brien, M. Keating, T. Manshouri, C. Gidel, B. Barlogie, M. Beran, C. Koller, H. Kantarjian, and M. Albitar
Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia
Blood, July 15, 2000; 96(2): 768 - 770.
[Abstract] [Full Text] [PDF]

J. W. Baish and R. K. Jain
Fractals and Cancer
Cancer Res., July 1, 2000; 60(14): 3683 - 3688.
[Abstract] [Full Text]

F. Bertolini, L. Fusetti, P. Mancuso, A. Gobbi, C. Corsini, P. F. Ferrucci, G. Martinelli, and G. Pruneri
Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma
Blood, July 1, 2000; 96(1): 282 - 287.
[Abstract] [Full Text] [PDF]

A. W. Griffioen and G. Molema
Angiogenesis: Potentials for Pharmacologic Intervention in the Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation
Pharmacol. Rev., June 1, 2000; 52(2): 237 - 268.
[Abstract] [Full Text] [PDF]

L. Fusetti, G. Pruneri, A. Gobbi, C. Rabascio, N. Carboni, F. Peccatori, G. Martinelli, and F. Bertolini
Human Myeloid and Lymphoid Malignancies in the Non-Obese Diabetic/Severe Combined Immunodeficiency Mouse Model: Frequency of Apoptotic Cells in Solid Tumors and Efficiency and Speed of Engraftment Correlate with Vascular Endothelial Growth Factor Production
Cancer Res., May 1, 2000; 60(9): 2527 - 2534.
[Abstract] [Full Text]

T. Padro, S. Ruiz, R. Bieker, H. Burger, M. Steins, J. Kienast, T. Buchner, W. E. Berdel, and R. M. Mesters
Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
Blood, April 15, 2000; 95(8): 2637 - 2644.
[Abstract] [Full Text] [PDF]

R. S. Kerbel
Tumor angiogenesis: past, present and the near future
Carcinogenesis, March 1, 2000; 21(3): 505 - 515.
[Abstract] [Full Text] [PDF]

				D. Cervi, T.-T. Yip, N. Bhattacharya, V. N. Podust, J. Peterson, A. Abou-Slaybi, G. N. Naumov, E. Bender, N. Almog, J. E. Italiano Jr, et al. Platelet-associated PF-4 as a biomarker of early tumor growth Blood, February 1, 2008; 111(3): 1201 - 1207. [Abstract] [Full Text] [PDF]

				E. Zetterberg, A. M. Vannucchi, A. R. Migliaccio, W. Vainchenker, M. Tulliez, R. Dickie, H. Hasselbalch, R. Rogers, and J. Palmblad Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows Haematologica, May 1, 2007; 92(5): 597 - 604. [Abstract] [Full Text] [PDF]

				D. Cervi, Y. Shaked, M. Haeri, T. Usenko, C. R. Lee, J. J. Haigh, A. Nagy, R. S. Kerbel, E. Yefenof, and Y. Ben-David Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia Blood, March 1, 2007; 109(5): 2139 - 2146. [Abstract] [Full Text] [PDF]

				S. Shalapour, A. Zelmer, M. Pfau, E. Moderegger, C. Costa-Blechschmidt, F. K.H. van Landeghem, T. Taube, I. Fichtner, C. Buhrer, G. Henze, et al. The Thalidomide Analogue, CC-4047, Induces Apoptosis Signaling and Growth Arrest in Childhood Acute Lymphoblastic Leukemia Cells In vitro and In vivo. Clin. Cancer Res., September 15, 2006; 12(18): 5526 - 5532. [Abstract] [Full Text] [PDF]

				S. Indraccolo, L. Stievano, S. Minuzzo, V. Tosello, G. Esposito, E. Piovan, R. Zamarchi, L. Chieco-Bianchi, and A. Amadori Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. PNAS, March 14, 2006; 103(11): 4216 - 4221. [Abstract] [Full Text] [PDF]

				W. Liu, M. Guo, Y.-B. Xu, D. Li, Z.-N. Zhou, Y.-L. Wu, Z. Chen, S. C. Kogan, and G.-Q. Chen Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia Blood, January 15, 2006; 107(2): 698 - 707. [Abstract] [Full Text] [PDF]

				W. Fureder, M.-T. Krauth, W. R. Sperr, K. Sonneck, I. Simonitsch-Klupp, L. Mullauer, M. Willmann, H.-P. Horny, and P. Valent Evaluation of Angiogenesis and Vascular Endothelial Growth Factor Expression in the Bone Marrow of Patients with Aplastic Anemia Am. J. Pathol., January 1, 2006; 168(1): 123 - 130. [Abstract] [Full Text] [PDF]

				L. F. Costa, M. Balcells, E. R. Edelman, L. M. Nadler, and A. A. Cardoso Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-{kappa}B Blood, January 1, 2006; 107(1): 285 - 292. [Abstract] [Full Text] [PDF]

				S. Faderl, K.-A. Do, M. M. Johnson, M. Keating, S. O'Brien, I. Jilani, A. Ferrajoli, F. Ravandi-Kashani, C. Aguilar, A. Dey, et al. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia Blood, December 15, 2005; 106(13): 4303 - 4307. [Abstract] [Full Text] [PDF]

				M. Chavez-MacGregor, A. Aviles-Salas, D. Green, A. Fuentes-Alburo, C. Gomez-Ruiz, and A. Aguayo Angiogenesis in the Bone Marrow of Patients with Breast Cancer Clin. Cancer Res., August 1, 2005; 11(15): 5396 - 5400. [Abstract] [Full Text] [PDF]

				Y. Shaked, D. Cervi, M. Neuman, L. Chen, G. Klement, C. R. Michaud, M. Haeri, B. J. Pak, R. S. Kerbel, and Y. Ben-David The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells Blood, June 1, 2005; 105(11): 4500 - 4507. [Abstract] [Full Text] [PDF]

				K. Podar and K. C. Anderson The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood, February 15, 2005; 105(4): 1383 - 1395. [Abstract] [Full Text] [PDF]

				J. LeCouter, C. Zlot, M. Tejada, F. Peale, and N. Ferrara Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization PNAS, November 30, 2004; 101(48): 16813 - 16818. [Abstract] [Full Text] [PDF]

				M G Alexandrakis, F H Passam, C Dambaki, C A Pappa, and E N Stathopoulos The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma J. Clin. Pathol., August 1, 2004; 57(8): 856 - 860. [Abstract] [Full Text] [PDF]

				S. Kumar, T. E. Witzig, and S. V. Rajkumar Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies J. Clin. Oncol., June 15, 2004; 22(12): 2477 - 2488. [Abstract] [Full Text] [PDF]

				H. X. Chen Expanding the Clinical Development of Bevacizumab Oncologist, June 1, 2004; 9(suppl_1): 27 - 35. [Abstract] [Full Text] [PDF]

				A. Ruddell, P. Mezquita, K. A. Brandvold, A. Farr, and B. M. Iritani B Lymphocyte-Specific c-Myc Expression Stimulates Early and Functional Expansion of the Vasculature and Lymphatics during Lymphomagenesis Am. J. Pathol., December 1, 2003; 163(6): 2233 - 2245. [Abstract] [Full Text]

				F. J. Giles, A. T. Stopeck, L. R. Silverman, J. E. Lancet, M. A. Cooper, A. L. Hannah, J. M. Cherrington, A.-M. O'Farrell, H. A. Yuen, S. G. Louie, et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes Blood, August 1, 2003; 102(3): 795 - 801. [Abstract] [Full Text] [PDF]

				X. Chen, Z. Ai, M. Rasmussen, P. Bajcsy, L. Auvil, M. Welge, L. Leach, S. Vangveeravong, A. J. Maniotis, and R. Folberg Three-Dimensional Reconstruction of Extravascular Matrix Patterns and Blood Vessels in Human Uveal Melanoma Tissue: Techniques and Preliminary Findings Invest. Ophthalmol. Vis. Sci., July 1, 2003; 44(7): 2834 - 2840. [Abstract] [Full Text] [PDF]

				G. Schuch, M. Machluf, G. Bartsch Jr, M. Nomi, H. Richard, A. Atala, and S. Soker In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo Blood, December 15, 2002; 100(13): 4622 - 4628. [Abstract] [Full Text] [PDF]

REGULAR ARTICLES

Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia

				P. O. Iversen, C. A. Drevon, and J. E. Reseland Prevention of leptin binding to its receptor suppresses rat leukemic cell growth by inhibiting angiogenesis Blood, December 1, 2002; 100(12): 4123 - 4128. [Abstract] [Full Text] [PDF]

				F. A. Scappaticci Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies J. Clin. Oncol., September 15, 2002; 20(18): 3906 - 3927. [Abstract] [Full Text] [PDF]

				E. S. J. M. de Bont, V. Fidler, T. Meeuwsen, F. Scherpen, K. Hahlen, and W. A. Kamps Vascular Endothelial Growth Factor Secretion Is an Independent Prognostic Factor for Relapse-free Survival in Pediatric Acute Myeloid Leukemia Patients Clin. Cancer Res., September 1, 2002; 8(9): 2856 - 2861. [Abstract] [Full Text] [PDF]

				L. Hlatky, P. Hahnfeldt, and J. Folkman Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us J Natl Cancer Inst, June 19, 2002; 94(12): 883 - 893. [Full Text] [PDF]

				R. A. Mesa, C. A. Hanson, C.-Y. Li, S.-Y. Yoon, S. V. Rajkumar, G. Schroeder, and A. Tefferi Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia Blood, May 13, 2002; 99(11): 4131 - 4137. [Abstract] [Full Text] [PDF]

				F. Wimazal, J.-H. Jordan, W. R. Sperr, A. Chott, S. Dabbass, K. Lechner, H. P. Horny, and P. Valent Increased Angiogenesis in the Bone Marrow of Patients with Systemic Mastocytosis Am. J. Pathol., May 1, 2002; 160(5): 1639 - 1645. [Abstract] [Full Text] [PDF]

				M. E. El-Sabban, R. A. Merhi, H. A. Haidar, B. Arnulf, H. Khoury, J. Basbous, J. Nijmeh, H. de The, O. Hermine, and A. Bazarbachi Human T-cell lymphotropic virus type 1-transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells Blood, May 1, 2002; 99(9): 3383 - 3389. [Abstract] [Full Text] [PDF]

				S. Dias, M. Choy, K. Alitalo, and S. Rafii Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy Blood, March 15, 2002; 99(6): 2179 - 2184. [Abstract] [Full Text] [PDF]

				R. Koomagi, F. Zintl, A. Sauerbrey, and M. Volm Vascular Endothelial Growth Factor in Newly Diagnosed and Recurrent Childhood Acute Lymphoblastic Leukemia as Measured by Real-Time Quantitative Polymerase Chain Reaction Clin. Cancer Res., November 1, 2001; 7(11): 3381 - 3384. [Abstract] [Full Text] [PDF]

				E. S. J. M. de Bont, J. E. J. Guikema, F. Scherpen, T. Meeuwsen, W. A. Kamps, E. Vellenga, and N. A. Bos Mobilized Human CD34+ Hematopoietic Stem Cells Enhance Tumor Growth in a Nonobese Diabetic/Severe Combined Immunodeficient Mouse Model of Human Non-Hodgkin's Lymphoma Cancer Res., October 1, 2001; 61(20): 7654 - 7659. [Abstract] [Full Text] [PDF]